
NTLA
Healthcare · Biotechnology · $1.36B market cap
$9.70-0.85 (-8.1%)Nov 13, 4:29 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -2.1% over 90 days · 30-day revisions 3 up, 4 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | Before the open | -0.82 | -0.91 | -11.0% |
| Aug 6, 2026 | Before the open | -0.80 | -0.80 | 0.0% |
| May 11, 2026 | Before the open | -0.90 | -0.81 | +10.0% |
| Feb 26, 2026 | Time not confirmed | -0.99 | -0.83 | +16.2% |
| Nov 6, 2025 | After the close | -0.98 | -0.92 | +6.1% |
| Aug 7, 2025 | Before the open | -1.03 | -0.99 | +3.9% |
| May 8, 2025 | Before the open | -1.27 | -1.10 | +13.4% |
| Feb 20, 2025 | Before the open | -1.32 | -1.27 | +3.5% |
| Nov 7, 2024 | Before the open | -1.37 | -1.34 | +2.2% |
| Aug 8, 2024 | Before the open | -1.20 | -1.52 | -26.7% |
| May 9, 2024 | Before the open | -1.36 | -1.12 | +17.6% |
| Feb 22, 2024 | Before the open | -1.44 | -1.46 | -1.4% |
| Nov 9, 2023 | Before the open | -1.50 | -1.38 |
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.…
| +8.0% |
| Aug 3, 2023 | Before the open | -1.33 | -1.40 | -5.3% |
| May 4, 2023 | After the close | -1.38 | -1.17 | +15.2% |
| Feb 23, 2023 | Before the open | -1.39 | -1.40 | -0.7% |
| Nov 3, 2022 | After the close | -1.25 | -1.49 | -19.2% |
| Aug 4, 2022 | Before the open | -1.30 | -1.33 | -2.3% |
| May 5, 2022 | Before the open | -1.11 | -1.96 | -76.6% |
| Feb 24, 2022 | Before the open | -0.94 | -1.09 | -16.0% |
| Nov 4, 2021 | Before the open | -0.85 | -0.97 | -14.1% |
| Aug 5, 2021 | Before the open | -0.61 | -1.01 | -65.6% |
| May 6, 2021 | Before the open | -0.66 | -0.69 | -4.5% |
| Feb 25, 2021 | Before the open | -0.61 | -0.69 | -13.1% |
| Nov 5, 2020 | Before the open | -0.57 | -0.47 | +17.5% |
| Aug 6, 2020 | Before the open | -0.67 | -0.61 | +9.0% |
| May 7, 2020 | Before the open | -0.42 | -0.63 | -50.0% |
| Feb 27, 2020 | Before the open | -0.56 | -0.57 | -1.8% |
| Oct 31, 2019 | Before the open | -0.61 | -0.49 | +19.7% |
| Aug 1, 2019 | Before the open | -0.59 | -0.56 | +5.1% |
| May 2, 2019 | Before the open | -0.57 | -0.49 | +14.0% |
| Feb 27, 2019 | Before the open | -0.56 | -0.43 | +23.2% |
| Oct 31, 2018 | Before the open | -0.49 | -0.53 | -8.2% |
| Aug 1, 2018 | Before the open | -0.56 | -0.52 | +7.1% |
| May 1, 2018 | Before the open | -0.56 | -0.51 | +8.9% |
| Mar 14, 2018 | Before the open | -0.42 | -0.61 | -45.2% |